Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Aug
20
Today In Oncology
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL
Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo